Stanford biotech spinout snares $100M round on path toward IPO

The South San Francisco company has raised more than $250 million since its 2013 launch targeting a protein that could hold the key to treating neurodegenerative, autoimmune and eye diseases.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.